Aigen Investment Management LP Has $513,000 Position in Immunocore Holdings plc (NASDAQ:IMCR)

Aigen Investment Management LP reduced its position in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 26.2% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,471 shares of the company’s stock after selling 5,840 shares during the period. Aigen Investment Management LP’s holdings in Immunocore were worth $513,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IMCR. Exchange Traded Concepts LLC raised its stake in shares of Immunocore by 40.4% in the third quarter. Exchange Traded Concepts LLC now owns 5,075 shares of the company’s stock valued at $158,000 after acquiring an additional 1,461 shares during the last quarter. Connective Portfolio Management LLC bought a new position in Immunocore in the 3rd quarter valued at $218,000. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 69.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after purchasing an additional 3,053 shares in the last quarter. DNB Asset Management AS grew its holdings in shares of Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock worth $244,000 after purchasing an additional 1,868 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Immunocore in the second quarter valued at $303,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

Immunocore stock opened at $32.62 on Friday. The firm has a market capitalization of $1.63 billion, a P/E ratio of -34.34 and a beta of 0.72. The business has a 50-day moving average of $32.52 and a 200-day moving average of $38.89. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 1 year low of $29.72 and a 1 year high of $76.98.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.50. The firm had revenue of $80.25 million during the quarter, compared to analysts’ expectations of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.59) earnings per share. On average, equities analysts anticipate that Immunocore Holdings plc will post -0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

IMCR has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Thursday, October 24th. Oppenheimer reissued an “outperform” rating and issued a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. Needham & Company LLC dropped their price objective on shares of Immunocore from $78.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday, September 9th. Finally, UBS Group started coverage on Immunocore in a research note on Thursday, October 24th. They issued a “sell” rating and a $24.00 target price for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Immunocore has an average rating of “Moderate Buy” and a consensus target price of $69.18.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.